Your new experience awaits. Try the new design now and help us make it even better

CORRECTION article

Front. Oncol.

Sec. Cancer Immunity and Immunotherapy

Volume 15 - 2025 | doi: 10.3389/fonc.2025.1645247

This article is part of the Research TopicInnovative Therapeutic Approaches for Complex Cancers: Exploring New StrategiesView all 12 articles

Correction: Enhanced anti‑tumor efficacy of “IL‑15 and CCL19” ‑secreting CAR‑T cells in human glioblastoma orthotopic xenograft model

Provisionally accepted
Wanqiong ChenWanqiong Chen1Limian HongLimian Hong2Shaomei LinShaomei Lin1Na XianNa Xian3,4Cailing YanCailing Yan5Ningning ZhaoNingning Zhao6Yonglei XiaoYonglei Xiao3Wanting LiaoWanting Liao1Yuxiang HuangYuxiang Huang1Mingzhu ChenMingzhu Chen1*
  • 1School of Pharmacy, Quanzhou Medical College, Quanzhou, China
  • 2Department of Pharmacy, Quanzhou First Hospital Affiliated to Fujian Medical University, Quanzhou, China
  • 3Institute of Immunotherapy, Fujian Medical University, Fuzhou, China
  • 4Tcelltech Biological Science and Technology Inc, Fuzhou, China
  • 5Public Technology Service Center, Fujian Medical University, Fuzhou, China
  • 6Laboratory Animal Center, Fujian Medical University, Fuzhou, China

This article is a correction to:

  1. Enhanced anti-tumor efficacy of "IL-15 and CCL19" -secreting CAR-T cells in human glioblastoma orthotopic xenograft model

    1. Read original article

The final, formatted version of the article will be published soon.

Select one of your emails

You have multiple emails registered with Frontiers:

Notify me on publication

Please enter your email address:

If you already have an account, please login

You don't have a Frontiers account ? You can register here

Correction on: Chen W, Hong L, Lin S, Xian N, Yan C, Zhao N, Xiao Y, Liao W, Huang Y and Chen M (2025) Enhanced anti-tumor efficacy of "IL-15 and CCL19" -secreting CAR-T cells in human glioblastoma orthotopic xenograft model. Front. Oncol. 15:1539055. doi: 10.3389/fonc.2025.1539055 In the published article, there was an error in Figure 4B as published. During figure compilation, the image intended to represent the first mouse in the UTD group was erroneously placed as the third mouse in the EGFRvIII CAR group on day 7 post-tumor-cell injection, resulting in image duplication in Figure 4B. This was an unintentional error in image placement. We apologize for this error and state that this does not change the scientific conclusions of the article. The corrected Figure 4B and its caption appear below.

Keywords: CAR-T cells, Glioblastoma, IL-15, CCL19, cancer immunotherapy, EGFRvIII

Received: 11 Jun 2025; Accepted: 24 Jul 2025.

Copyright: © 2025 Chen, Hong, Lin, Xian, Yan, Zhao, Xiao, Liao, Huang and Chen. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

* Correspondence: Mingzhu Chen, School of Pharmacy, Quanzhou Medical College, Quanzhou, China

Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.

Supplementary Material